Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $3 | $3 |
| % Growth | -100% | -50.4% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $1 | $3 | $3 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $6 | $9 | $28 | $21 |
| G&A Expenses | $6 | $8 | $14 | $6 |
| SG&A Expenses | $6 | $8 | $16 | $6 |
| Sales & Mktg Exp. | $0 | -$0 | $2 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $17 | $43 | $27 |
| Operating Income | -$13 | -$16 | -$41 | -$24 |
| % Margin | – | -1,176.8% | -1,502% | -896.2% |
| Other Income/Exp. Net | -$3 | $21 | $3 | $1 |
| Pre-Tax Income | -$16 | $5 | -$38 | -$23 |
| Tax Expense | $3 | $0 | $0 | -$3 |
| Net Income | -$19 | $6 | -$38 | -$22 |
| % Margin | – | 412.3% | -1,397.1% | -822.7% |
| EPS | -0.47 | 0.14 | -0.97 | -0.78 |
| % Growth | -435.7% | 114.4% | -24.4% | – |
| EPS Diluted | -0.47 | 0.14 | -0.97 | -0.78 |
| Weighted Avg Shares Out | 41 | 40 | 39 | 28 |
| Weighted Avg Shares Out Dil | 41 | 41 | 39 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $8 | $4 | $0 |
| Interest Expense | $1 | $4 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $4 | $0 |
| EBITDA | -$15 | $7 | -$37 | -$25 |
| % Margin | – | 546.3% | -1,368% | -926.3% |